Published in Am J Pathol on August 01, 1991
Traction force microscopy of migrating normal and H-ras transformed 3T3 fibroblasts. Biophys J (2001) 4.01
CD44H regulates tumor cell migration on hyaluronate-coated substrate. J Cell Biol (1992) 2.28
Ribosomal S6 kinase (RSK) regulates phosphorylation of filamin A on an important regulatory site. Mol Cell Biol (2004) 1.81
Absence of filamin A prevents cells from responding to stiffness gradients on gels coated with collagen but not fibronectin. Biophys J (2009) 1.70
Epac increases melanoma cell migration by a heparan sulfate-related mechanism. Am J Physiol Cell Physiol (2009) 1.54
Microinjection of the catalytic fragment of myosin light chain kinase into dividing cells: effects on mitosis and cytokinesis. J Cell Biol (1991) 1.47
Isolation of mouse stromal cells associated with a human tumor using differential diphtheria toxin sensitivity. Am J Pathol (1999) 1.33
msg1, a novel melanocyte-specific gene, encodes a nuclear protein and is associated with pigmentation. Proc Natl Acad Sci U S A (1996) 1.27
Prognostic significance of Sox4 expression in human cutaneous melanoma and its role in cell migration and invasion. Am J Pathol (2010) 1.08
RSK in tumorigenesis: connections to steroid signaling. Steroids (2010) 1.08
Phosphorylation of eIF4E promotes EMT and metastasis via translational control of SNAIL and MMP-3. Oncogene (2014) 1.04
Latrunculin A and its C-17-O-carbamates inhibit prostate tumor cell invasion and HIF-1 activation in breast tumor cells. J Nat Prod (2008) 0.95
Pro-prion binds filamin A, facilitating its interaction with integrin beta1, and contributes to melanomagenesis. J Biol Chem (2010) 0.95
Complex roles of filamin-A mediated cytoskeleton network in cancer progression. Cell Biosci (2013) 0.95
Mechanism of DNA damage responses induced by exposure to an oligonucleotide homologous to the telomere overhang in melanoma. Oncotarget (2013) 0.89
Targeting c-Met in melanoma: mechanism of resistance and efficacy of novel combinatorial inhibitor therapy. Cancer Biol Ther (2014) 0.88
Systems analysis of apoptosis protein expression allows the case-specific prediction of cell death responsiveness of melanoma cells. Cell Death Differ (2013) 0.85
Absence of RIPK3 predicts necroptosis resistance in malignant melanoma. Cell Death Dis (2015) 0.81
Role of BMP-4 and Its Signaling Pathways in Cultured Human Melanocytes. Int J Cell Biol (2009) 0.80
The fatal attraction between pro-prion and filamin A: prion as a marker in human cancers. Biomark Med (2010) 0.80
Decreased expression of nuclear p300 is associated with disease progression and worse prognosis of melanoma patients. PLoS One (2013) 0.79
Binding of pro-prion to filamin A: by design or an unfortunate blunder. Oncogene (2010) 0.78
Filamin A-hinge region 1-EGFP: a novel tool for tracking the cellular functions of filamin A in real-time. PLoS One (2012) 0.76
Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst (1989) 5.28
A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma. Hum Pathol (1984) 3.21
Relation between cell activity and the distribution of cytoplasmic actin and myosin. J Cell Biol (1981) 2.36
Characteristics of cultured human melanocytes isolated from different stages of tumor progression. Cancer Res (1985) 1.85
Organization and function of stress fibers in cells in vitro and in situ. A review. Cell Muscle Motil (1984) 1.85
Selective elimination of fibroblasts from cultures of normal human melanocytes. In Vitro (1984) 1.54
The biologic forms of malignant melanoma. Hum Pathol (1986) 1.51
Altered organization of cell-substrate contacts and membrane-associated cytoskeleton in tumor cell variants exhibiting different metastatic capabilities. Cancer Res (1982) 1.41
Growth inhibition of murine melanoma and human colon carcinoma by recombinant human platelet factor 4. J Natl Cancer Inst (1990) 1.37
Modulation of keratinocyte motility. Correlation with production of extracellular matrix molecules in response to growth promoting and antiproliferative factors. Am J Pathol (1988) 1.29
Motility and adhesive properties of high- and low-metastatic murine neoplastic cells. Cancer Res (1984) 1.19
The relationship of fibroblast translocations to cell morphology and stress fibre density. J Cell Sci (1982) 1.12
Cell configuration and adhesive properties of metastasizing and non-metastasizing BSp73 rat adenocarcinoma cells. Exp Cell Res (1986) 0.99
Actin filament organization of the Dunning R3327 rat prostatic adenocarcinoma system: correlation with metastatic potential. Cancer Res (1986) 0.98
Comparison of tumor cell invasion assays: human amnion versus reconstituted basement membrane barriers. Invasion Metastasis (1989) 0.92
Biochemical mechanisms of tumor invasion and metastases. Adv Exp Med Biol (1988) 0.90
Loss of metastatic responsiveness to cell shape modulation in a newly characterized B16 melanoma adhesive cell variant. Cancer Res (1988) 0.85
Actin organization, cell motility, and metastasis. Adv Exp Med Biol (1988) 0.83
Spontaneous capillary tube migration of metastatic rat mammary adenocarcinoma cells. Invasion Metastasis (1984) 0.82
Altered expression of a third actin accompanying malignant progression in mouse B16 melanoma cells. Jpn J Cancer Res (1989) 0.81
Biochemical analysis of metastasis-related Ax actin in B16 mouse melanoma cells after chemical reversional modulation and of tumor progression-related A' actin in the ontogeny of human malignant melanoma. Pigment Cell Res (1990) 0.81
The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res (1969) 13.27
High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C--dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes (2000) 4.55
Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer (1996) 4.46
Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm). Intergroup Melanoma Surgical Trial. Ann Surg Oncol (2000) 3.42
A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure. Circulation (2000) 2.94
GLUT1: a newly discovered immunohistochemical marker for juvenile hemangiomas. Hum Pathol (2000) 2.86
Role of the clotting system in cell-mediated hypersensitivity. I. Fibrin deposition in delayed skin reactions in man. J Exp Med (1973) 2.75
Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Ann Surg (1996) 2.68
The classification of malignant melanoma and its histologic reporting. Cancer (1973) 2.67
Nonfamilial cutaneous melanoma incidence in women associated with sun exposure before 20 years of age. Pediatrics (1989) 2.61
Atypical Spitz nevi/tumors: lack of consensus for diagnosis, discrimination from melanoma, and prediction of outcome. Hum Pathol (1999) 2.50
Common and uncommon melanocytic nevi and borderline melanomas. Semin Oncol (1975) 2.36
Melanoma in children. N Engl J Med (1995) 2.35
Benign cutaneous adnexal tumors with combined folliculosebaceous, apocrine, and eccrine differentiation. Clinicopathologic and immunohistochemical study of eight cases. Am J Dermatopathol (1996) 2.30
Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1 to 4 mm). Results of a multi-institutional randomized surgical trial. Ann Surg (1993) 2.08
Long-term results of a prospective surgical trial comparing 2 cm vs. 4 cm excision margins for 740 patients with 1-4 mm melanomas. Ann Surg Oncol (2001) 2.06
Kimura's disease and angiolymphoid hyperplasia with eosinophilia: two distinct histopathological entities. J Cutan Pathol (1987) 1.92
Automatic differentiation of melanoma from melanocytic nevi with multispectral digital dermoscopy: a feasibility study. J Am Acad Dermatol (2001) 1.91
Nonepidermal origin of malignant melanoma associated with a giant congenital nevocellular nevus. Plast Reconstr Surg (1981) 1.86
Dermal dendritic melanocytic proliferations: an update. Histopathology (2004) 1.84
Narrower margins for clinical stage I malignant melanoma. N Engl J Med (1982) 1.82
Primary melanoma of the skin: recognition and management. J Am Acad Dermatol (1980) 1.82
A new immunologic marker for human Langerhans cells. N Engl J Med (1981) 1.79
A unique microvascular phenotype shared by juvenile hemangiomas and human placenta. Arch Dermatol (2001) 1.77
An estimate of the annual direct cost of treating cutaneous melanoma. J Am Acad Dermatol (1998) 1.76
Melasma: a clinical, light microscopic, ultrastructural, and immunofluorescence study. J Am Acad Dermatol (1981) 1.76
Basophilic leukocytes in allergic contact dermatitis. J Exp Med (1972) 1.75
Melastatin expression and prognosis in cutaneous malignant melanoma. J Clin Oncol (2001) 1.75
Rejection of first-set skin allografts in man. the microvasculature is the critical target of the immune response. J Exp Med (1979) 1.74
Long-term quality of life after laparoscopy-assisted distal gastrectomy for gastric cancer. Surg Endosc (2007) 1.73
Characterization of Langerhans cells by the use of monoclonal antibodies. Lab Invest (1981) 1.73
Prognostic factors for melanoma patients with lesions 0.76 - 1.69 mm in thickness. An appraisal of "thin" level IV lesions. Ann Surg (1982) 1.72
Ultra-late recurrence (15 years or longer) of cutaneous melanoma. Cancer (1997) 1.71
Dysplastic melanocytic nevi: a reproducible histologic definition emphasizing cellular morphology. Mod Pathol (1989) 1.71
Pilomatrix carcinoma or calcifying epitheliocarcinoma of Malherbe: a case report and review of literature. Cancer (1980) 1.70
Morphology of delayed-type hypersensitivity reactions in man. II. Ultrastructural alterations affecting the microvasculature and the tissue mast cells. Lab Invest (1976) 1.70
Morphology of delayed type hypersensitivity reactions in man. I. Quantitative description of the inflammatory response. Lab Invest (1974) 1.68
Lentigo maligna and lentigo-maligna melanoma. Am J Pathol (1969) 1.68
Squamoid eccrine ductal carcinoma. Histopathology (1997) 1.67
The clinical diagnosis, classification and histogenetic concepts of the early stages of cutaneous malignant melanomas. N Engl J Med (1971) 1.65
Does biopsy type influence survival in clinical stage I cutaneous melanoma? J Am Acad Dermatol (1985) 1.64
Matrix metalloproteinase inhibition attenuates left ventricular remodeling and dysfunction in a rat model of progressive heart failure. Circulation (2001) 1.59
Studies on the cellular origin of neurothekeoma: clinical, light microscopic, immunohistochemical, and ultrastructural observations. J Am Acad Dermatol (1991) 1.59
Histopathologic diagnosis of dysplastic nevi: concordance among pathologists convened by the World Health Organization Melanoma Programme. Hum Pathol (1991) 1.54
Bullous dermatosis of hemodialysis. Ann Intern Med (1975) 1.47
Marginal zone lymphoma (low-grade B-cell lymphoma of mucosa-associated lymphoid tissue type) of skin and subcutaneous tissue: a study of 15 patients. Am J Surg Pathol (1996) 1.45
The natural break points for primary-tumor thickness in clinical Stage I melanoma. N Engl J Med (1981) 1.45
Actin-binding protein expression in benign and malignant melanocytic proliferations. Hum Pathol (1994) 1.44
Origin of cutaneous melanoma in a congenital dysplastic nevus spilus. Arch Dermatol (1990) 1.43
Early melanoma. Histologic terms. Am J Dermatopathol (1991) 1.43
Acral lentiginous melanoma (including in situ melanoma) arising in association with naevocellular naevi. Melanoma Res (1996) 1.42
Adjuvant high-dose interferon alfa-2b in patients with high-risk melanoma. Cancer J (2000) 1.41
Topical axitinib suppresses angiogenesis pathways induced by pulsed dye laser. Br J Dermatol (2014) 1.40
A prognostic model for clinical stage I melanoma of the upper extremity. The importance of anatomic subsites in predicting recurrent disease. Ann Surg (1981) 1.38
Prognostic factors for patients with clinical stage I melanoma of intermediate thickness (1.51 - 3.39 mm). A conceptual model for tumor growth and metastasis. Ann Surg (1982) 1.38
Sun exposure habits in patients with cutaneous melanoma: a case control study. J Dermatol Surg Oncol (1983) 1.37
Congenital melanocytic nevi of the small and garment type. Clinical, histologic, and ultrastructural studies. Hum Pathol (1973) 1.36
Bullous pemphigoid, an ultrastructural study of the inflammatory response: eosinophil, basophil and mast cell granule changes in multiple biopsies from one patient. J Invest Dermatol (1982) 1.35
Angiogenesis and tumor progression of melanoma. Quantification of vascularity in melanocytic nevi and cutaneous malignant melanoma. Lab Invest (1992) 1.34
Malignant melanoma. Prognostic significance of "microscopic satellites" in the reticular dermis and subcutaneous fat. Ann Surg (1981) 1.34
A prognostic model for clinical stage I melanoma of the lower extremity. Location on foot as independent risk factor for recurrent disease. Surgery (1981) 1.33
Desmoplastic neurotropic melanoma. A clinicopathologic analysis of 28 cases. Cancer (1995) 1.33
Prevalence of germ-line mutations in p16, p19ARF, and CDK4 in familial melanoma: analysis of a clinic-based population. Proc Natl Acad Sci U S A (1996) 1.31
Risk factors for cutaneous melanoma. A practical method of recognizing predisposed individuals. JAMA (1987) 1.30
Inhibition of melanogenesis as an adjuvant strategy in the treatment of melanotic melanomas: selective review and hypothesis. Anticancer Res (1999) 1.29
Constitutive activation of Wnt/beta-catenin signaling pathway in migration-active melanoma cells: role of LEF-1 in melanoma with increased metastatic potential. Biochem Biophys Res Commun (2001) 1.28
Lack of allelic deletion and point mutation as mechanisms of p53 activation in human malignant melanoma. Int J Cancer (1993) 1.27
Neutrophilic eccrine hidradenitis. A distinctive type of neutrophilic dermatosis associated with myelogenous leukemia and chemotherapy. Arch Dermatol (1982) 1.27
Transplacental leakage of HBeAg-positive maternal blood as the most likely route in causing intrauterine infection with hepatitis B virus. J Pediatr (1987) 1.26
A multivariate analysis of prognostic factors for melanoma patients with lesions greater than or equal to 3.65 mm in thickness. The importance of revealing alternative Cox models. Ann Surg (1982) 1.24
Cellular neurothekeoma. A distinctive variant of neurothekeoma mimicking nevomelanocytic tumors. Am J Surg Pathol (1990) 1.23
T6 is superior to Ia (HLA-DR) as a marker for Langerhans cells and indeterminate cells in normal epidermis: a monoclonal antibody study. J Invest Dermatol (1983) 1.23
The risk of progression of lentigo maligna to lentigo maligna melanoma. Br J Dermatol (1987) 1.23
Major histocompatibility antigens and mononuclear inflammatory infiltrate in benign nevomelanocytic proliferations and malignant melanoma. J Immunol (1982) 1.21
The human sunburn reaction: histologic and biochemical studies. J Am Acad Dermatol (1981) 1.20
Confocal scanning laser microscopy of benign and malignant melanocytic skin lesions in vivo. J Am Acad Dermatol (2001) 1.20
Sunlight and skin cancer. N Engl J Med (1985) 1.20
T cell subsets and Langerhans cells in lichen planus: in situ characterization using monoclonal antibodies. Br J Dermatol (1981) 1.19
Degranulation of basophilic leukocytes in allergic contact dermatitis reactions in man. J Immunol (1976) 1.18
The structure of normal skin and the morphology of atopic eczema. J Invest Dermatol (1976) 1.18
Minimal deviation melanoma: a histologic variant of cutaneous malignant melanoma in its vertical growth phase. J Invest Dermatol (1983) 1.17